Recurrence-free survival after curative resection of non-small cell lung cancer between inhalational gas anesthesia and propofol-based total intravenous anesthesia: a multicenter, randomized, clinical trial (GAS TIVA trial): protocol description
Authors:
Open Access
- 23 July 2024
- journal article
- research article
- Published by Springer Nature in Perioperative Medicine
- Vol. 13 (1) , 1-12
Abstract
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC), but microscopic residual disease may be unavoidable. Preclinical studies have shown that volatile anesthetics might suppress host immunity and promote a pro-malignant environment that supports cancer cell proliferation, migration, and angiogenesis, whereas propofol may preserve cell-mediated immunity and inhibit tumor angiogenesis. However, clinical evidence that propofol-based total intravenous anesthesia (TIVA) can reduce tumor recurrence after curative resection remains inconsistent due to the retrospective observational nature of previous studies. Therefore, we will test the hypothesis that the recurrence-free survival (RFS) after curative resection of NSCLC is higher in patients who received TIVA than volatile anesthetics (GAS) in this multicenter randomized trial. Methods: This double-blind, randomized trial will enroll patients at 22 international sites, subject to study registration, institutional review board approval, and patient written informed consent. Eligible patients are adult patients undergoing lung resection surgery with curative intent for NSCLC. Exclusion criteria will be contraindications to study drugs, American Society of Anesthesiologists physical status IV or higher, or preexisting distant metastasis or malignant tumor in other organs. At each study site, enrolled subjects will be randomly allocated into the TIVA and GAS groups with a 1:1 ratio. This pragmatic trial does not standardize any aspect of patient care. However, potential confounders will be balanced between the study arms. The primary outcome will be RFS. Secondary outcomes will be overall survival and complications within postoperative 7 days. Enrollment of 5384 patients will provide 80% power to detect a 3% treatment effect (hazard ratio of 0.83) at alpha 0.05 for RFS at 3 years. Discussion: Confirmation of the study hypothesis would demonstrate that a relatively minor and low-cost alteration in anesthetic management has the potential to reduce cancer recurrence risk in NSCLC, an ultimately fatal complication. Rejection of the hypothesis would end the ongoing debate about the relationship between cancer recurrence and anesthetic management. Trial registration: The study protocol was prospectively registered at the Clinical trials (https://clinicaltrials.gov, NCT06330038, principal investigator: Hyun Joo Ahn; date of first public release: March 25, 2024) before the recruitment of the first participant.Keywords
Funding Information
- Samsung Medical Center (2022, # PHO0224701, 2015 #OTX0003201)
This publication has 61 references indexed in Scilit:
- Potential role of the autonomic nervous system in the immunosuppressive effects of acute morphine administrationEuropean Journal of Pharmacology, 1996
- Perioperative Normothermia to Reduce the Incidence of Surgical-Wound Infection and Shorten HospitalizationNew England Journal of Medicine, 1996
- Haematogenous dissemination of prostatic epithelial cells during radical prostatectomyThe Lancet, 1995
- Morphine Inhibits Spontaneous and Cytokine-enhanced Natural Killer Cell Cytotoxicity in VolunteersAnesthesiology, 1995
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity.The Journal of Pharmacology and Experimental Therapeutics, 1994
- Inhibition of Interferon Stimulation of Natural Killer Cell Activity in Mice Anesthetized with Halothane or IsofluraneAnesthesiology, 1993
- Covariate adjustment of treatment effects in clinical trialsControlled Clinical Trials, 1991
- Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors.Journal of Clinical Investigation, 1981
- Invasion of tumor cells into the bloodstream caused by palpation or biopsy of the tumor.1966